{
    "_id": "38066905|None",
    "id": "38066905",
    "infons": {},
    "passages": [
        {
            "infons": {
                "journal": "Hematology Am Soc Hematol Educ Program;2023Dec08; 2023 (1) 519. doi:10.1182/hematology.2023000485",
                "year": "2023",
                "article-id_pmc": "PMC10727073",
                "type": "title",
                "authors": "Rai P, Ataga KI, "
            },
            "offset": 0,
            "text": "Using disease-modifying therapies in sickle cell disease.",
            "sentences": [],
            "annotations": [
                {
                    "id": "1",
                    "infons": {
                        "identifier": "MESH:D000755",
                        "type": "Disease",
                        "valid": true,
                        "normalized": [
                            "D000755"
                        ],
                        "database": "ncbi_mesh",
                        "normalized_id": "D000755",
                        "biotype": "disease",
                        "name": "Anemia Sickle Cell",
                        "accession": "@DISEASE_Anemia_Sickle_Cell"
                    },
                    "text": "sickle cell disease",
                    "locations": [
                        {
                            "offset": 37,
                            "length": 19
                        }
                    ]
                }
            ],
            "relations": []
        },
        {
            "infons": {
                "type": "abstract"
            },
            "offset": 58,
            "text": "As curative therapy using allogeneic hematopoietic stem cell transplantation as well as gene therapy and gene editing remains inaccessible to most patients with sickle cell disease, the availability of drug therapies that are safe, efficacious, and affordable is highly desirable. Increasing progress is being made in developing drug therapies based on our understanding of disease pathophysiology. Four drugs, hydroxyurea, L-glutamine, crizanlizumab, and voxelotor, are currently approved by the US Food and Drug Administration, with multiple others at various stages of testing. With the limited efficacy of individual agents, combinations of agents will likely be required for optimal outcomes.",
            "sentences": [],
            "annotations": [
                {
                    "id": "4",
                    "infons": {
                        "identifier": "9606",
                        "type": "Species",
                        "valid": true,
                        "normalized": [
                            9606
                        ],
                        "database": "ncbi_taxonomy",
                        "normalized_id": 9606,
                        "biotype": "species",
                        "name": "9606",
                        "accession": null
                    },
                    "text": "patients",
                    "locations": [
                        {
                            "offset": 205,
                            "length": 8
                        }
                    ]
                },
                {
                    "id": "5",
                    "infons": {
                        "identifier": "MESH:D000755",
                        "type": "Disease",
                        "valid": true,
                        "normalized": [
                            "D000755"
                        ],
                        "database": "ncbi_mesh",
                        "normalized_id": "D000755",
                        "biotype": "disease",
                        "name": "Anemia Sickle Cell",
                        "accession": "@DISEASE_Anemia_Sickle_Cell"
                    },
                    "text": "sickle cell disease",
                    "locations": [
                        {
                            "offset": 219,
                            "length": 19
                        }
                    ]
                }
            ],
            "relations": []
        }
    ],
    "relations": [],
    "pmid": 38066905,
    "pmcid": null,
    "meta": {},
    "date": "2023-12-08T00:00:00Z",
    "journal": "Hematology Am Soc Hematol Educ Program",
    "authors": [
        "Rai P",
        "Ataga KI"
    ],
    "relations_display": []
}